Filtered By:
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 47 results found since Jan 2013.
Acute angle closure glaucoma following COVID-19 vaccination
Therapie. 2023 Jun 7:S0040-5957(23)00082-3. doi: 10.1016/j.therap.2023.06.002. Online ahead of print.NO ABSTRACTPMID:37321945 | PMC:PMC10246303 | DOI:10.1016/j.therap.2023.06.002
Source: Therapie - June 15, 2023 Category: Psychiatry & Psychology Authors: Yasmine Salem Mahjoubi Israa Dahmani Ines Souilem Imen Aouinti Sarrah Kastalli Riadh Daghfous Sihem El Aidli Source Type: research
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
COVID-19 Vaccine-Associated Ocular Adverse Effects: An Overview
CONCLUSIONS: Evidence regarding the ocular adverse effects does not outweigh the benefits of SARS-CoV-2 vaccination in patients with pre-existing systemic or ophthalmic diseases. This review provides insights into the possible temporal association between reported ocular adverse events and SARS-CoV-2 vaccines; however, further investigations are required to identify the link between potential causality and pathological mechanisms.PMID:36366386 | DOI:10.3390/vaccines10111879
Source: Herpes - November 11, 2022 Category: Infectious Diseases Authors: Parul Ichhpujani Uday Pratap Singh Parmar Siddharth Duggal Suresh Kumar Source Type: research
